Bevacizumab (anti-VEGF)S53563 · CAS 216974-75-3
无载体, 重组, 低内毒素, 无叠氮钠, 已验证, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
无载体, 重组, 低内毒素, 无叠氮钠, 已验证, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
促销97%
97%
≥95%
95%
≥95%
促销98%
average Mn ~468, EO/phenol 1.5, contains MEHQ as inhibitor
促销99%
≥95%
98%
≥98%
≥95%
95%
≥98 atom% D,≥98%
≥98 atom% D,≥96%
≥98 atom% D, stabilized with 0.1% propylene oxide
98%
96%
98%
促销≥98%(GC)
促销≥99%
≥95%, contains ≤6000 ppm hydroquinone as stabilizer
促销98%